Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681, Vol. 02, Issue No. 02, 2025 (pp. 43-58)

REVIEW ARTICLE https://aktpublication.com/index.php/jprims/index

Drug Delivery Methods Based on Nanoparticles for The Management of Cardiovascular Disorders

[1*]Harshlata Kanwar, [1]Rashmi Chanda

[1]KIPS, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India, 491001

*Corresponding Author E-mail: harshalatakanwar25@gmail.com

ABSTRACT

Nanoparticle drug delivery systems have evolved as a revolutionary approach to the treatment of cardiovascular diseases (CVDs). These systems present a highly hopeful alternative to traditional drugs, which often have limited bioavailability, systemic toxicity, poor solubility, and a dearth of targeted therapeutic effect. Liposomal, polymeric, metallic, and dendrimer-based nanoparticles are just a few examples of nanoscale carriers that can deliver drugs to injured tissues in a targeted fashion. This facilitates controlled and sustained drug release while at the same time reducing off-targeting effects. Nanotechnology can potentially enhance therapeutic responses significantly by aiding in the stabilization of medication, circulation time, and cellular internalization. This, in turn, will help to reduce unwanted effects and enhance patient care. The application of nanoparticles in tissue engineering is not only limited to the delivery of drugs but also plays a critical role in the regeneration of heart tissue and function as good contrast agents for imaging purposes, allowing for real-time monitoring of diseases. However, despite their enormous promise, their widespread clinical use is hampered by obstacles such as the toxicity of nanoparticles, the quick clearance of the immune system, intricacy of manufacture on a large scale, and onerous regulatory approval procedures. The effective integration of nanoparticle therapeutics with traditional cardiovascular treatment will depend upon the successful solution of these issues through the creation of biocompatible materials, effective surface modifications, and scalable manufacturing processes. Under the purview of this research, the latest advances in drug delivery through nanotechnology are explored, the mechanisms by which therapeutic action is enhanced are explored, and the potential future directions for implementing these advances into cardiovascular therapy protocols are explored.

Key Words:
Nanoparticle, Drug Delivery Systems, Cardiovascular Disorders (CVD), Low Bioavailability, Systemic Toxicity, Poor Solubility, Nanoscale Carriers, Liposomal, Polymeric, Metallic, Nanotechnology, Cardiovascular Treatment Strategies.

.

Article History:

Received Jan 25,2025

Accepted Feb 16,2025

Published Feb 28 ,2025

1. INTRODUCTION

Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, and hence there is a continuous demand for the creation of more effective therapeutic strategies. Current traditional methods of delivering cardiovascular disease (CVD) drugs face multiple limitations including insufficient bioavailability and drug insolubility together with systemic toxicity and nontargeted distribution of medications. Advanced pharmacological and surgical treatment methods exist but do not resolve this problem. Suboptimum treatment outcomes together with increased possibilities of adverse effects occur because of these identified challenges. Nanotechnology serves as a solution to resolve existing challenges through its demonstrated promising benefits. Nanotechnology enables targeted drug delivery alongside controlled drug release functions while improving treatment effectiveness at specific locations. Nanoparticles (NPs) hold the lead position in this technological revolution because they function as very effective drug carriers for cardiovascular drugs while improving drug stability while delivering medication to specific affected tissues. Due to their versatility, they are not only used in drug delivery but also in tissue engineering and imaging, making them a versatile tool in cardiovascular medicine. Nanotechnology ought to be applied into cardiovascular therapy since it has the ability to revolutionize treatment paradigms through the delivery of therapeutic modalities that are more effective, personalized, and less invasive [1].

Due to their unique physicochemical properties, biocompatibility, and ability to bypass biological barriers, nanoparticle-based drug delivery systems, namely liposomal, polymeric, and metallic nanoparticles, have been the focus of a great deal of interest. Polymeric nanoparticles enable controlled release and sustained delivery of drugs, while liposomal nanoparticles enhance the solubilization of drugs and circulation half-life [2]. Metallic nanoparticles like gold and silver nanoparticles have also demonstrated potential for imaging and theranostic uses. The nanoparticles can potentially allow real-time monitoring of illness along with therapy. However, even with these promising advances, there are several challenges that bar their extensive clinical use. Issues of toxicity, immunogenicity, large-scale manufacturing, and regulatory approval remain key challenges. In an effort to ensure the efficacy and safety of nanomedicine-based treatments, rigorous preclinical and clinical validation should be undertaken. Additionally, for the purpose of generating reproducible and reliable results, uniformity in the synthesis, characterisation, and delivery of nanoparticles needs to be ensured. If these challenges are overcome and laboratory progress is brought forward to clinically viable treatments, then the future of nanotechnology in cardiovascular medicine will be promising. This review aims to give a complete insight into the role played by nanotechnology by looking at recent developments, discussing the different delivery systems based on nanoparticles, and assessing the prospects for the future.



Figure 1: Drug delivery methods based on nanoparticles for the management of heart condition [3]

1.1. Background and Context

According to World Health Organization (WHO) data cardiovascular diseases (CVDs) stand as the leading cause of worldwide deaths which result in 17.9 million annual fatalities. The disease categories recognize coronary artery disease, heart failure and hypertension and stroke among others. These diseases produce substantial burdens for worldwide healthcare institutions. Traditional medical procedures suffer from multiple issues because drugs show inadequate absorption rates while producing systemic toxicities without precise actions that result in underperforming therapeutic benefits. These significant advancements in pharmacotherapy have occurred despite them all [4].

The development of improved drug delivery techniques using nanotechnology enhances cardiovascular therapy accuracy while delivering better effects and ensuring patient safety which represents a promising medical solution for these challenges. Nanoparticles demonstrate outstanding capabilities for reducing drug delivery to incorrect areas while enhancing drug stability as well as drug solubility and providing drug release at detailed locations. Studies focus on several nanocarrier concepts that serve drug delivery purposes in the cardiovascular system. The nanocarriers produce drug delivery systems from dendrimers as well as polymeric nanoparticles and metallic nanoparticles and liposomes. These nanoscale platforms serve as an innovative cardiovascular medical tool since they permit controlled drug delivery while simultaneously improving bioavailability through targeted therapeutic options [5].

1.2. Objectives of the Review

This review aims to:

- To examine how nanoparticles are used in medication delivery, tissue engineering, and imaging in order to better understand their function in the therapy of CVD [6].
- To examine the mechanisms of action of various nanoparticle-based drug delivery methods, such as metallic, polymeric, and liposomal nanoparticles.
- To assess safety, regulatory, and large-scale clinical translation hurdles, as well as the potential of nanotechnology in cardiovascular care [7].

1.3. Importance of the Topic

The medical care for cardiological diseases now experiences fundamental changes because nanotechnology enhances drug delivery systems [8]. Nanoparticles serve as effective drug delivery platforms because their controlled medication release pattern ensures maximum treatment benefit by lowering drug-related side effects. Nanoscale platforms find applications as theranostic medications since they integrate both diagnostic tools and therapeutic delivery components within one system. Early diagnosis of diseases requires this important foundation to create specific treatment approaches [9].

Healthcare needs treatment approaches that deliver safer outcomes while bettering the medical results currently achieved because cardiovascular disease continues to expand its global impact. The acquisition of knowledge about nanotechnology's therapeutic potential for heart system drug delivery could pave the way for creating new treatment procedures that would yield better healthcare results through reduced expenses. This research aims to create a thorough evaluation of contemporary discoveries, problems, and potential evolution in nanoparticle medical interventions for cardiovascular systems [10].

2. ADVANCEMENTS IN NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS FOR CARDIOVASCULAR DISORDERS

Modern drug delivery systems utilizing nanoparticles have transformed how healthcare professionals treat cardiovascular diseases. The drug delivery methods succeed in enhancing pharmaceutical stability while increasing drug availability and allowing targeted drug distribution. The sophisticated drug delivery systems address traditional limitations by overcoming systemic toxicity and drug degradation and poor drug distribution. Scientific experts built multiple delivery platforms capable of controlling drug release duration while minimizing negative effects and delivering better therapeutic results. Researchers use distinctive physicochemical properties of nanoparticles to produce these platforms. The following section describes different types of drug delivery systems based on nanoparticles along with their operational mechanisms while exploring their applications in cardiovascular medication [11].



Figure 2: Systems of Drug Delivery for Cardiovascular Diseases [12]

i. Types of Nanoparticle-Based Drug Delivery Systems

Nanoparticles used for delivering drugs in the cardiovascular system receive their classification through their structural properties and functional capabilities together with their material components. Liposomal nanoparticles are among the leading nanoparticle research subjects alongside polymeric nanoparticles and metallic nanoparticles which are further joined by magnetic and dendrimers nanoparticles [13].

Liposomal nanoparticles containing lipid bilayers achieve powerful medication solubility while extending the medication duration in circulation and improving cellular drug absorption. Hydrophobic drug delivery and nucleic acid-based therapy benefit significantly from nanoparticles that serve in atherosclerosis and myocardial infarction disease management. Controlled drug delivery through polymeric nanoparticles made of synthetic or natural polymers such as chitosan and PLGA results in extended medication effects which allows for decreased drug administration. Scientists have investigated anti-inflammatory agents and antihypertensive drugs as potential cardiovascular disease (CVD) treatment through nanoparticles [14].

Due to their unique optical and electrical properties, metallic nanoparticles like gold and silver nanoparticles find utility in many applications, from imaging and drug

delivery. For targeted drug delivery for vascular disease, gold nanoparticles specifically have been shown to possess a lot of potential. Dendrimers, which are highly branched, nanoscale polymers, can achieve the targeted delivery of drugs through surface functionalization. This increases the therapeutic effectiveness while at the same time lowering the occurrence of off-target effects. When used in theranostic procedures, magnetic nanoparticles enable imaging to be carried out in real time while, at the same time, delivering drugs to specific cardiovascular tissues. This is achieved under an external magnetic field.

ii. Mechanisms of Action in Cardiovascular Therapy

Various techniques like passive targeting, active targeting, and stimuli-responsive drug release are employed by nanoparticles for the improvement of drug delivery in the treatment of cardiovascular diseases [15].

Nanoparticles can aggregate in injured or inflamed cardiovascular tissues by employing passive targeting, which utilizes the enhanced permeability and retention (EPR) effect. This leads to dramatically enhanced drug localization. Functionalized nanoparticles that are designed with ligands, antibodies, or peptides that specifically bind to receptors on ill endothelium cells are employed in active targeting. This process guarantees the medicine is dispensed in the right way. Using stimulus-responsive drug release, drugs are released from nanoparticles due to physiological stimuli like pH change, temperature change, or enzymatic activity. This guarantees that the drugs are triggered at the specific site where they are required.

iii. Applications of Nanoparticle-Based Drug Delivery in CVD Treatment

There is a wide range of potential uses for medication delivery systems that are based on nanoparticles in the treatment of cardiovascular disease [16].

In the therapy of atherosclerosis, nanoparticles enable the administration of anti-inflammatory and lipid-lowering drugs to atherosclerotic plaques in a targeted fashion, thus assisting in preventing the advancement of the disease. In the therapy of thrombosis, nanocarriers enhance the efficiency of anticoagulant and thrombolytic drugs and decrease the risk of systemic bleeding. Another fascinating subject is cardiac regeneration, where stem cell-loaded nanoparticles and growth factor delivery systems are used to promote the healing of myocardial tissue following a heart attack. Polymeric nanoparticles have also been explored for the treatment of hypertension. These nanoparticles provide a sustained release of antihypertensive drugs, which is useful for the long-term control of blood pressure [17].

iv. Advantages Over Conventional Drug Delivery Methods

Relative to more conventional methods of drug delivery, nanoparticle-based drug delivery possesses several beneficial features. These include higher targeting efficiency that reduces off-target effects, prolonged circulation time and controlled drug release, reduced systemic toxicity and side effects, improved bioavailability and drug stability, and lower systemic toxicity and side effects. Furthermore, nanoparticles are also capable of being combined with imaging methods through the use of theranostic applications [18]. This would enable the integration of diagnostic and treatment under one platform.

These findings show the potential of nanotechnology in transforming cardiovascular treatment and its potential potential. The widespread clinical adoption of these nanovesicles requires resolution of toxicity issues and manufacturing difficulties as well as regulatory barriers. A thorough overview of these issues accompanies future prospects which we will discuss in detail in the following section [19].

3. CHALLENGES AND FUTURE PERSPECTIVES IN NANOTECHNOLOGY FOR CARDIOVASCULAR THERAPY

The field of cardiovascular medicine has discovered new possibilities through nanotechnology which provides tailored drug delivery systems together with better bioavailability and minimized systemic toxicity. The enormous potential exists for nanotechnology in medical applications however numerous obstacles prevent its full-scale clinical deployment [20]. The transition of nanoparticle-based medical treatments from research settings to medical practice requires solving these present limitations. This segment examines vital nanotechnology obstacles in cardiovascular therapy and establishes potential ways to boost therapeutic methods for future use.



Figure 3: Cardiovascular Treatment [21]

3.1. Challenges in Nanotechnology for Cardiovascular Therapy

Biocompatibility remains as the main challenge for nanoparticle-based drug delivery systems because scientists aim to balance both safety and toxicity levels. Due to their capability of inducing cytotoxicity, oxidative stress, or inflammatory response, some nanoparticles, particularly those composed of synthetic polymers and metal materials, have been found. There is immense ignorance regarding the long-term impacts of nanoparticle deposition in tissue, and for this reason, there is a need for tremendous in vivo testing to assess the

safety profile of the particles. Another major hindrance to effective cardiovascular therapy is the attainment of controlled and long-term medication delivery. Nanoparticles must be formulated in a manner that maintains drug stability during circulation and also guarantees that the medicine is delivered exactly and accurately localized to the ailing site. Yet, the success of therapeutic strategies can be significantly affected by numerous conditions, such as nanoparticle degradation, premature drug release, and unforeseen pharmacokinetics. The large-scale manufacturing of nanoparticles with uniform quality characteristics and homogeneous sizes along with reproducible properties continues to represent a major manufacturing obstacle. Changes made in the synthesis production methods create random effects on drug loading properties along with particle stability characteristics and functionalization outcomes. The development of production methods which combine cost-efficiency and scalable operation and GMP compliance becomes essential [22].

The complex regulatory framework poses an additional difficulty to nanoparticle-based therapies as it makes their clinical development and research needs to overcome multiple barriers. The established medication approval systems seem unable to address nanoparticles effectively since nanotechnology is still emerging in medical practice. Safety along with standard quality and maximum effectiveness from nanoparticle treatments is achieved through extensive preclinical and clinical trials performed as per FDA and EMA standards. The required process of approval gets postponed because of this method. Fast nanoparticle clearance via the immune system presents the second major difficulty because it reduces both treatment effectiveness and the amount of time nanoparticles stay inside the body. Before nanoparticles can reach their designated target site they undergo two common body defenses including macrophage phagocytosis and renal clearance mechanisms. The solution proposed to address this issue consists of surface modification through polyethylene glycol (PEGylation) or biomimetic coatings according to current research efforts. The scientific community focuses on improving nanoparticle compatibility with biological systems as well as extending their circulation period within the body and enhancing their durability [23].

3.2. Future Perspectives in Nanotechnology for Cardiovascular Therapy

Nanoparticle therapeutic development advances through precision medicine approaches to produce unique patient-specific treatments for medical patients. Future cardiovascular disease biomarker-targeting nanoparticles show potential for optimized therapeutic outcomes through specific biomarker selectivity which also reduces the occurrence of adverse side effects. ATE PACT disease management in cardiology will benefit from the future use of nanoparticles that combine diagnosis with treatment functions under a single platform known as theranostics [24]. Theranostic nanoparticles allow real-time imaging and illness monitoring so doctors can use controlled drug release systems. Such developments allow clinicians to provide patients with treatments matching their unique medical requirements and better treatment outcomes.

Researchers have started developing nanoparticles capable of responding to healthcare signals such as pH changes and temperature variations and enzyme reactions through drug release mechanisms. These innovative drug delivery platforms show promise by simultaneously decreasing systemic side effects so they could enhance treatment accuracy. Bioinspired and biomimetic nanoparticles that copy natural cell membrane characteristics and extracellular vesicle features help increase both therapeutic strength and biological compatibility. Through escaping immune system detection, the nanoparticles enhance the potency of targeting as well as increasing the percentage of medicine remaining in the site of the disease [25].

It is imperative that researchers, clinicians, and regulatory authorities collaborate to successfully translate these advances into clinical practice. To fill the gap between laboratory research and clinical use, investments in large-scale clinical trials, harmonization of regulatory needs, and building strong relationships between the academic and business communities must be made. The development of nanoparticle-based cardiovascular therapies and the integration of these treatments into mainstream medical practice will be facilitated to a large extent by such collaborative research efforts [26].

Table 1: References table

Authors	Study	Focus Area	Methodology	Key Findings
Paunovska et al. (2022) [27]	Drug delivery systems for RNA therapeutics	Lipid-based, polymeric, and inorganic carriers for RNA delivery	Literature review of RNA-based drug delivery strategies	Targeted delivery and stability enhancement improve RNA therapeutics.
Pinelli et al. (2020) [28]	In vivo drug delivery applications of nanogels	Biocompatibility, controlled release, and physiological response of nanogels	Review of nanogel applications in drug delivery	Nanogels enhance drug retention and hold promise for personalized medicine.
Pramanik et al. (2021) [29]	Nanoparticle-based drug delivery for chronic pulmonary diseases	Targeted pulmonary drug delivery and bioavailability enhancement	Review of nanoparticle applications in treating lung diseases	Nanoparticles improve drug bioavailability and reduce side effects.
Qiao et al. (2023) [30]	Magnetic iron oxide nanoparticles for brain	Brain-targeted drug delivery and neuroimaging	Review of magnetic iron oxide nanoparticles	Magnetic nanoparticles can cross the blood-brain barrier for

	imaging and drug delivery		and their medical applications	neurotherapeutic use.
Satapathy et al. (2021) [31]	Solid lipid nanoparticles (SLNs) for brain drug delivery	SLNs as drug carriers across the blood-brain barrier (BBB)	Review of SLNs in CNS drug delivery	SLNs offer stability, biocompatibility, and sustained drug release in the brain.
Sharma et al. (2021) [32]	Toxicology of nanoparticles in drug delivery	Cytotoxicity, immunogenicity, and long-term effects of nanoparticles	Review of nanoparticle toxicology	Safety concerns require rigorous toxicity assessments before clinical application.

4. DISCUSSION

Liposomal, polymeric, metallic, dendrimer, and magnetic nanoparticles have demonstrated great promise as future drug delivery systems for cardiovascular diseases. Nanoparticle-based drug delivery systems are more bioavailable, offer customized therapy, and are less toxic [33]. The medical breakthroughs enabled by theranostic capabilities along with cardiac tissue regeneration face hinderance in clinical translation because of toxicity, immune clearance barriers and production scale problems and regulatory difficulties [34]. To bridge existing gaps and produce cardiovascular treatments that work safely the medical field needs to focus on making biocompatible nanoparticles while improving targeting efficacy and optimizing large-scale manufacturing and developing smart drug delivery systems and conducting clinical trials with regulatory approval [35].

4.1. Interpret and Analyze the Findings

This review covers how nanoparticle-based drug delivery systems had advanced significantly for cardiovascular disease treatments. The bioavailability of drugs and targeted therapeutic functions along with reduced systemic toxicity mark these systems as highly effective. Medical researchers have identified five different nanoparticle categories including liposomal, polymeric, metallic, dendrimer and magnetic nanoparticles for cardiovascular drug delivery [36]. All nanoparticle varieties present different zones of benefits including specific drug delivery features alongside elongated bloodstream presence and diagnostic help functions. The group of compounds known as dendrimer nanoparticles serves as potential carriers. The optimization of therapeutic effectiveness through drug delivery systems that use passive and active targeting mechanisms together with stimuli-responsive drug release assists in directing medications to predetermined sites. The translation process faces multiple barriers because of toxicity risks and immune system clearance and difficulties in expanding large-scale

manufacturing. Therapeutic effectiveness along with cardiovascular treatment safety based on nanoparticles depends on removing the current barriers.

4.2. Discuss Implications and Significance

Medical treatment of cardiovascular disease underwent a fundamental transformation through the incorporation of nanotechnology in healthcare. New targeted drug treatment selections with personalized features and reduced invasiveness have been developed through this method. Improved drug stability combined with less off-target effects through nanoparticle-based delivery systems presents a potentially big opportunity to advance patient results as well as reduce healthcare costs. In addition, its theranostic potential, which integrates therapeutic and diagnostic functions within one platform, holds the promise of a revolutionary opportunity for early disease detection, real-time monitoring, and best treatment choices [37]. This potential is revolutionary in the medical field. The ability of nanoparticles to promote the regeneration of cardiac tissue has important implications for recovery after a myocardial infarct as well as for the therapy of chronic cardiovascular disease. To take full advantage of these benefits, however, more research needs to be conducted to optimize nanoparticle formulations and delivery systems.

4.3. Research Gaps

In spite of promising progress in drug delivery using nanoparticles for cardiovascular disease, there are still many open issues that should be addressed:

- **Toxicity and Biocompatibility:** Nobody has an absolute idea about the impact of nanoparticles on the health of humans in the long term [38]. There are some types of nanoparticles that are polymeric and liposomal, which have a very good level of biocompatibility. However, some other types of nanoparticles, for example, metallic nanoparticles, are capable of creating oxidative stress as well as inflammation.
- **Immune Clearance and Stability:** A large number of nanoparticles is rapidly cleared away by the immune system, lowering the therapeutic benefits of the particles. Further refinement is needed on the approaches targeting to enhance the circulation time and stability.
- **Standardization and Large-Scale Production:** Inconsistencies in drug loading efficiency, stability, and functionalization are due to the lack of established methodologies for the synthesis and characterization of nanoparticles. To enable clinical translation, manufacturing procedures need to be scalable and in accordance with regulatory standards.
- **Regulatory Challenges:** There is a lag in the approval of nanoparticle-based therapies and their integration into standard clinical practice because there are no regulatory guidelines that are clearly defined for these treatments. There is a need for clear recommendations for the assessment of toxicity, the planning of clinical trials, and the determination of safety.

4.4. Suggest Future Research Directions

In order to overcome such challenges and simplify the translation of nanoparticle-based

drug delivery systems into the clinical setting, research in the future should focus on the following aspects:

- **Developing Safer and More Biocompatible Nanoparticles:** It is important that research focuses on nanoparticles that are biodegradable and bioinspired, with a view to achieving minimal toxicity and immune clearance with maximum therapeutic effectiveness [39].
- **Enhancing Targeting Efficiency:** It is crucial to explore more sophisticated surface functionalization approaches, including ligand or antibody conjugation, to improve active targeting and ensure precise drug delivery to cardiovascular tissues.
- **Optimizing Large-Scale Manufacturing:** To enable mass production while maintaining quality and consistency, it is crucial to create methods for nanoparticle synthesis that are economical, reproducible, and scalable.
- **Exploring Smart and Responsive Drug Delivery Systems:** Drugs could be delivered from nanoparticles in response to physiological signals, e.g., pH or enzymatic changes. This would permit more therapeutic precision while at the same time lowering the potential for unwanted effects.
- **Advancing Clinical Trials and Regulatory Harmonization:** Additional substantial preclinical along with clinical studies need to be conducted to validate the safety and efficacy and pharmacokinetic properties of nanoparticle-based cardiovascular therapy [40]. Speeding up the approval process while keeping to global safety requirements becomes possible due to partnership between researchers, industry leaders and regulatory agencies.

5. CONCLUSION

Drug administration through nanoparticles presents modern medicine with a groundbreaking therapeutic option for cardiovascular diseases since they enhance drug solubility and enable precise tissue targeting while maintaining drug stability and decreasing treatment-related side effects. Therapeutic agent delivery to specific targets occurs through nanoscale vehicles that consist of liposomes and polymeric nanoparticles and lipid-based formulations. The therapeutic benefits increase through this approach and the system simultaneously reduces potential adverse side effects. Extensive clinical application of nanoparticle platforms remains limited because of three main technical barriers alongside toxicity concerns and immunogenic properties and production scaleup requirements and stability challenges and rigid regulatory requirements. Although significant progress was made in developing various nanoparticle platforms the reality remains different from this assessment. The complete therapeutic use of nanoparticles for cardiovascular disease requires substantial preclinical and clinical evaluation while implementing specialized research methods and multidisciplinary collaboration. Nanomedicine will revolutionize future cardiovascular treatment through its development of improved safe delivery protocols which combine individual patient profiles with enhanced therapies. Nanomedicine treatment approaches yield

beneficial effects for patient results while diminishing the worldwide incidence of cardiovascular diseases.

REFERENCES

1. Afzal, O., Altamimi, A. S., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., ... & Kazmi, I. (2022). Nanoparticles in drug delivery: From history to therapeutic applications. *Nanomaterials*, *12*(24), 4494.
2. Ashok, A., Andrabi, S. S., Mansoor, S., Kuang, Y., Kwon, B. K., & Labhasetwar, V. (2022). Antioxidant therapy in oxidative stress-induced neurodegenerative diseases: Role of nanoparticle-based drug delivery systems in clinical translation. *Antioxidants*, *11*(2), 408.
3. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020). Polymeric nanoparticles for drug delivery: Recent developments and future prospects. *Nanomaterials*, *10*(7), 1403.
4. Chandrakala, V., Aruna, V., & Angajala, G. (2022). Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems. *Emergent Materials*, *5*(6), 1593-1615.
5. Cheng, X., Xie, Q., & Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. Frontiers in bioengineering and biotechnology, 11, 1177151.
6. Deng, Y., Zhang, X., Shen, H., He, Q., Wu, Z., Liao, W., & Yuan, M. (2020). Application of the nano-drug delivery system in treatment of cardiovascular diseases. *Frontiers in bioengineering and biotechnology*, *7*, 489.
7. Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. *Heliyon*, *9*(6).
8. Fan, C., Joshi, J., Li, F., Xu, B., Khan, M., Yang, J., & Zhu, W. (2020). Nanoparticle-mediated drug delivery for treatment of ischemic heart disease. *Frontiers in bioengineering and biotechnology*, *8*, 687.
9. Gao, C., Huang, Q., Liu, C., Kwong, C. H., Yue, L., Wan, J. B., ... & Wang, R. (2020). Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. *Nature communications*, *11*(1), 2622.
10. Gao, C., Huang, Q., Liu, C., Kwong, C. H., Yue, L., Wan, J. B., ... & Wang, R. (2020). Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. *Nature communications*, *11*(1), 2622.
11. Garbayo, E., Pascual-Gil, S., Rodríguez-Nogales, C., Saludas, L., Estella-Hermoso de Mendoza, A., & Blanco-Prieto, M. J. (2020).

Nanomedicine and drug delivery systems in cancer and regenerative medicine. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, *12*(5), e1637.

12. Haleem, A., Javaid, M., Singh, R. P., Rab, S., & Suman, R. (2023). Applications of nanotechnology in medical field: a brief review. *Global Health Journal*, *7*(2), 70-77.

13. Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020). Protein-based nanoparticles as drug delivery systems. *Pharmaceutics*, *12*(7), 604.

14. Hu, Q., Fang, Z., Ge, J., & Li, H. (2022). Nanotechnology for cardiovascular diseases. *The Innovation*, *3*(2).

15. Idrees, H., Zaidi, S. Z. J., Sabir, A., Khan, R. U., Zhang, X., & Hassan, S. U. (2020). A review of biodegradable natural polymer-based nanoparticles for drug delivery applications. *Nanomaterials*, *10*(10), 1970.

16. Jan, N., Madni, A., Khan, S., Shah, H., Akram, F., Khan, A., ... & Ertas, Y. N. (2023). Biomimetic cell membrane-coated poly (lactic-co-glycolic acid) nanoparticles for biomedical applications. *Bioengineering & Translational Medicine*, *8*(2), e10441.

17. Khalilov, R. (2023). A comprehensive review of advanced nano-biomaterials in regenerative medicine and drug delivery. *Advances in Biology & Earth Sciences*, *8*(1).

18. Khan, A. U., Khan, M., Cho, M. H., & Khan, M. M. (2020). Selected nanotechnologies and nanostructures for drug delivery, nanomedicine and cure. *Bioprocess and biosystems engineering*, *43*(8), 1339-1357.

19. Liu, H., Su, Y. Y., Jiang, X. C., & Gao, J. Q. (2023). Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. *Drug Delivery and Translational Research*, *13*(3), 716-737.

20. Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., ... & Gao, H. (2023). Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. *Chinese chemical letters*, *34*(2), 107518.

21. Lou, J., Duan, H., Qin, Q., Teng, Z., Gan, F., Zhou, X., & Zhou, X. (2023). Advances in oral drug delivery systems: Challenges and opportunities. *Pharmaceutics*, *15*(2), 484.

22. Mirza, Z., & Karim, S. (2021, February). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. In *Seminars in cancer biology* (Vol. 69, pp. 226-237). Academic Press.

23. Namiot, E. D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2023). Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. *International journal of molecular sciences*, *24*(1), 787.

24. Pala, R., Anju, V. T., Dyavaiah, M., Busi, S., & Nauli, S. M. (2020).

Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases. *International journal of nanomedicine*, 3741-3769.

25. Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. *Journal of Controlled Release*, *342*, 53-65.

26. Park, J. H., Dehaini, D., Zhou, J., Holay, M., Fang, R. H., & Zhang, L. (2020). Biomimetic nanoparticle technology for cardiovascular disease detection and treatment. *Nanoscale horizons*, *5*(1), 25-42.

27. Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022). Drug delivery systems for RNA therapeutics. Nature Reviews Genetics, 23(5), 265-280.

28. Pinelli, F., Ortolà, Ó. F., Makvandi, P., Perale, G., & Rossi, F. (2020). In vivo drug delivery applications of nanogels: a review. *Nanomedicine*, *15*(27), 2707-2727.

29. Pramanik, S., Mohanto, S., Manne, R., Rajendran, R. R., Deepak, A., Edapully, S. J., ... & Katari, O. (2021). Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases. *Molecular Pharmaceutics*, *18*(10), 3671-3718.

30. Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., ... & Davis, T. P. (2023). Magnetic iron oxide nanoparticles for brain imaging and drug delivery. *Advanced Drug Delivery Reviews*, *197*, 114822.

31. Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. *Pharmaceutics*, *13*(8), 1183.

32. Sharma, S., Parveen, R., & Chatterji, B. P. (2021). Toxicology of nanoparticles in drug delivery. *Current pathobiology reports*, 1-12.

33. Sim, S., & Wong, N. K. (2021). Nanotechnology and its use in imaging and drug delivery. *Biomedical reports*, *14*(5), 42.

34. Sushnitha, M., Evangelopoulos, M., Tasciotti, E., & Taraballi, F. (2020). Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. *Frontiers in bioengineering and biotechnology*, *8*, 627.

35. Sushnitha, M., Evangelopoulos, M., Tasciotti, E., & Taraballi, F. (2020). Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. *Frontiers in bioengineering and biotechnology*, *8*, 627.

36. Wang, H., Zhou, Y., Sun, Q., Zhou, C., Hu, S., Lenahan, C., ... & Tao, S. (2021). Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. *Frontiers in Bioengineering and Biotechnology*, *9*, 630352.

37. Wu, Y., Wan, S., Yang, S., Hu, H., Zhang, C., Lai, J., ... & Wu, J. (2022).

Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. *Journal of nanobiotechnology*, *20*(1), 542.

38. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., ... & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. *Frontiers in molecular biosciences*, *7*, 193.

39. Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. *Molecules*, *25*(9), 2193.

40. Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023). Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. *Polymers*, *15*(7), 1596.